Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists
Sign Up to like & getrecommendations! Published in 2019 at "Drug Safety"
DOI: 10.1007/s40264-019-00812-7
Abstract: The prevalence of obesity and related comorbidities is increasing worldwide. Furthermore, clinically meaningful body weight losses has proven difficult to achieve and especially to maintain through sustained lifestyle change in the form of diet and… read more here.
Keywords: weight loss; obesity drugs; benefit risk; receptor ... See more keywords
Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs
Sign Up to like & getrecommendations! Published in 2019 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2020.1698291
Abstract: ABSTRACT Introduction: Obesity poses a significant increase in morbidity and mortality and thus five anti-obesity drugs have been approved currently by US FDA. Several phase 3 trials have shown a significant improvement in cardio-metabolic profile… read more here.
Keywords: obesity drugs; obesity; anti obesity; meta analysis ... See more keywords